Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Clin Cancer Res. 2021 Feb 26;27(11):2996–3004. doi: 10.1158/1078-0432.CCR-21-0066

Figure 2:

Figure 2:

(A) Best overall response according to RECIST criteria in the 41 evaluable patients who remained on this subprotocol. The number associated with each tumor designates the NRAS codon that was mutated. (B) treatment duration of the 24 patients whose best response was stable disease or a partial response. Abbreviations: Progressive disease (PD), stable disease (SD), and PR (partial response).